Skip to main content

Table 2 Subgroup analysis of VEGF levels in AML

From: Increased circulating vascular endothelial growth factor in acute myeloid leukemia patients: a systematic review and meta-analysis

Stratification group

N

SMD (95% CI)

Heterogeneity test

Publication bias

Q

P

I2 (%)

t

P

Total

14

0.85 (0.28 to 1.42)

146.87

< 0.001

91.1

− 0.75

0.467

Sample size

       

n ≥ 40

6

0.95 (0.14 to 1.77)

66.45

< 0.001

92.5

− 1.13

0.321

n < 40

8

0.77 (− 0.11 to 1.65)

80.21

< 0.001

91.3

− 0.92

0.392

Sample type

       

 Plasma

8

0.80 (0.16 to 1.44)

70.81

< 0.001

90.1

− 0.85

0.430

 Serum

6

0.93 (− 0.28 to 2.14)

75.64

< 0.001

93.4

− 0.66

0.545

Region

       

 Asia and Africa

11

1.09 (0.39 to 1.80)

119.16

< 0.001

91.6

− 0.22

0.828

 Europe and America

3

0.01 (− 0.28 to 0.31)

0.06

0.970

0.0

5.41

0.116

Age

       

 Age ≥ 45

2

2.05 (0.06 to 4.04)

19.71

< 0.001

94.9

NA

NA

 Age < 45

5

0.15 (− 0.64 to 0.93)

29.89

< 0.001

86.6

0.57

0.610

 Combined

7

0.69 (− 0.23 to 1.62)

89.84

< 0.001

93.3

0.25

0.809

  1. N number, SMD standard mean difference, CI confidence interval, AML acute myeloid leukemia, VEGF vascular endothelial growth factor